AnaptysBio, Inc. (ANAB): Price and Financial Metrics

AnaptysBio, Inc. (ANAB)

Today's Latest Price: $23.07 USD

0.73 (3.27%)

Updated Jul 1 6:55pm

Add ANAB to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

ANAB Stock Summary

  • The ratio of debt to operating expenses for Anaptysbio Inc is higher than it is for about only 0.3% of US stocks.
  • With a year-over-year growth in debt of -100%, Anaptysbio Inc's debt growth rate surpasses only 0% of about US stocks.
  • As for revenue growth, note that ANAB's revenue has grown 360% over the past 12 months; that beats the revenue growth of 98.17% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Anaptysbio Inc, a group of peers worth examining would be CARA, CRBP, MGNX, MORF, and VBLT.
  • ANAB's SEC filings can be seen here. And to visit Anaptysbio Inc's official web site, go to
ANAB Daily Price Range
ANAB 52-Week Price Range

ANAB Stock Price Chart Technical Analysis Charts

ANAB Price/Volume Stats

Current price $23.07 52-week high $56.72
Prev. close $22.34 52-week low $10.00
Day low $22.36 Volume 382,200
Day high $23.58 Avg. volume 518,116
50-day MA $19.25 Dividend yield N/A
200-day MA $20.12 Market Cap 629.28M

AnaptysBio, Inc. (ANAB) Company Bio

AnaptysBio Inc., an antibody development company, engages in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology in the Unites states. The company was founded in 2005 and is based in San Diego, California.

ANAB Latest News Stream

Event/TimeNews Detail
Loading, please wait...

ANAB Latest Social Stream

Loading social stream, please wait...

View Full ANAB Social Stream

Latest ANAB News From Around the Web

Below are the latest news stories about Anaptysbio Inc that investors may wish to consider to help them evaluate ANAB as an investment opportunity.

AnaptysBio, Inc. (ANAB) Upgraded to Buy: What Does It Mean for the Stock?

AnaptysBio, Inc. (ANAB) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | June 22, 2020

Hedge Funds Are Done Buying AnaptysBio, Inc. (ANAB)

Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]

Yahoo | June 15, 2020

Here's Why AnaptysBio Rose 22.1% in May

The beaten-up biopharma stock trekked higher after the development-stage company delivered a slew of pipeline updates alongside first quarter 2020 operating results. The small-cap stock has now gained 28% since the beginning of 2020, although shares of AnaptysBio have lost 73% in the last year. The development-stage company has forged collaborations with GlaxoSmithKline in cancer and Bristol-Myers Squibb in inflammatory diseases, which distributes risk and allows the business flexibility to pursue the development of wholly owned assets.

Yahoo | June 9, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AnaptysBio, Inc. - ANAB

Pomerantz LLP is investigating claims on behalf of investors AnaptysBio, Inc. (“AnaptysBio” or the “Company”) (ANAB). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. The investigation concerns whether AnaptysBio and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

Yahoo | May 27, 2020

SHAREHOLDER ALERT: ANAB HAFC WORX: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

NEW YORK, NY / ACCESSWIRE / May 26, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss ...

Yahoo | May 26, 2020

Read More 'ANAB' Stories Here

ANAB Price Returns

1-mo 13.42%
3-mo 63.62%
6-mo 52.78%
1-year -58.10%
3-year -7.76%
5-year N/A
YTD 41.97%
2019 -74.53%
2018 -36.67%
2017 N/A
2016 N/A
2015 N/A

Continue Researching ANAB

Here are a few links from around the web to help you further your research on Anaptysbio Inc's stock as an investment opportunity:

Anaptysbio Inc (ANAB) Stock Price | Nasdaq
Anaptysbio Inc (ANAB) Stock Quote, History and News - Yahoo Finance
Anaptysbio Inc (ANAB) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8903 seconds.